In all four major trials, despite substantial statistical power to detect a clinically meaningful treatment effect, the administration of sitagliptin, saxagliptin, alogliptin and omarigliptin did not reduce the combined risk of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke [47,48,49,50]
Natural compounds, such as L-carnitine, with antioxidant, anti-inflammatory, and lipid-modulating properties, are being explored as potential supplements to prevent and treat chronic diseases
Find the answers you seek below or on the general TUMS FAQ Page.
Eli Lillys Next-Generation GLP-1R Agonist NaperiglipronStructure Revealed | Eli Lilly has disclosed the structure of its next-generation small molecule GLP-1R agonist, naperiglipron (LY3549492)
E., Schepartz A
After the drugs were administered to the test subjects for 3 months they underwent the Morris water maze test